SCHEMBL3000340

SCHEMBL3000340

COc1ccc(Cc2csc(N3CCN(S(=O)(=O)c4ccccc4Cl)CC3)n2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.47
EPHX2 P34913 1/20 0.47
ALDH1A1 P00352 4/20 0.43
ALOX15 P16050 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
MAPT P10636 2/20 0.42
USP2 O75604 1/20 0.42
RECQL P46063 1/20 0.42
HSD17B10 Q99714 1/20 0.42
CHRM4 P08173 2/20 0.42
KCNQ1 P51787 1/20 0.42
LMNA P02545 4/20 0.41
MAPK1 P28482 3/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
POLB P06746 2/20 0.41
PKM P14618 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
RAB9A P51151 1/20 0.40
ACLY P53396 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3010955 0.93 ALDH1A1 (0.44) FAAHEPHX2ALDH1A1ALOX15TDP1
SCHEMBL3001787 0.91 MAPT (0.44) FAAHEPHX2ALDH1A1ALOX15MAPT
SCHEMBL3011190 0.91 MEN1 (0.44) FAAHEPHX2ALDH1A1TDP1MAPT
SCHEMBL3014108 0.90 MAPT (0.49) FAAHEPHX2ALDH1A1MAPTUSP2
SCHEMBL3003907 0.90 ALDH1A1 (0.45) ALDH1A1ALOX15TDP1MAPTUSP2
SCHEMBL2999775 0.89 FAAH (0.45) FAAHEPHX2ALDH1A1MAPTCHRM4
SCHEMBL3018427 0.89 MEN1 (0.46) EPHX2ALDH1A1MAPTCHRM4LMNA
SCHEMBL2997942 0.89 EPHX2 (0.48) FAAHEPHX2ALDH1A1MAPTCHRM4
SCHEMBL3012898 0.89 CHRM4 (0.47) FAAHEPHX2ALDH1A1MAPTCHRM4
SCHEMBL3014572 0.89 ACLY (0.46) ALDH1A1MAPTUSP2RECQLHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA FAAH 3111/4885EPHX2 4409/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.